How is Pfizer doing financially?

Pfizer's Financial Performance Overview

Assessing the financial health of pharmaceutical giant Pfizer reveals significant shifts in recent annual earnings, largely driven by the fluctuating demand for pandemic-related products and strategic portfolio expansions. Understanding these numbers provides a clearer picture of how the company navigates a post-pandemic market landscape.

In 2023, Pfizer recorded an annual revenue of $59.553 billion, which marked a notable 41.14% decline compared to the record-breaking figures posted in 2022. This steep drop-off was primarily attributed to a sharp decrease in global demand and sales for its COVID-19 vaccine and antiviral treatment.

However, the company experienced a rebound the following year. Pfizer's annual revenue for 2024 climbed to $63.627 billion, representing a 6.84% increase relative to 2023. This financial recovery was supported by targeted investments, solid commercial execution across its broader product portfolio, and contributions from newly integrated acquisitions, demonstrating the corporation's resilience and adaptability in a changing healthcare environment.